StockData
Summit Therapeutics Inc. logo

Summit Therapeutics Inc. (SMMT) stock

SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$10.67−1.15 (-9.73%)

Close on Nov 17, 2026Market cap $8.51BP/E –Yield –

Summit Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Summit Therapeutics's profit margin for the twelve months ending Jun 30, 2023 was -271685.0%. For fiscal 2022 it was -11174.8%, against -4897.8% the year before.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2022Dec 31, 2022-11174.8%−6276.9
FY2021Dec 31, 2021-4897.8%−4916.9
FY2019Jan 31, 201919.0%–

Quarterly profit margin

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange (pts)
Q3 FY2022CQ3 2022Sep 30, 2022-9720.5%−8223.2
Q2 FY2022CQ2 2022Jun 30, 2022-7136.6%+35698.5
Q1 FY2022CQ1 2022Mar 31, 2022-8558.8%+549.5
Q4 FY2021CQ4 2021Dec 31, 2021-10796.4%–
Q3 FY2021CQ3 2021Sep 30, 2021-1497.2%–
Q2 FY2021CQ2 2021Jun 30, 2021-42835.1%–
Q1 FY2021CQ1 2021Mar 31, 2021-9108.3%–

More Summit Therapeutics figures

See a number that looks wrong?